IPO registrations (S-1, F-1) · Registrants
Biohaven Pharmaceutical Holding Co Ltd.
- SEC CIK
- 1689813 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2017-04-07, last 2018-12-10; 4 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2017-05-05; declared effective 2017-05-03
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- D8
- Business address
- 215 CHURCH STREET, New Haven, CT 06510
- EDGAR entity type
- operating
- Insiders and CEO pay
- Biohaven Pharmaceutical Holding Co Ltd. on the corporate pages
Offering terms
- Final price
- $17.00 per share (424B4 filed 2017-05-05, an initial public offering)
- Shares sold
- 9,900,000
- Gross proceeds
- $168,300,000 before underwriting discounts and any over-allotment option
- Listing
- NYSE under the symbol BHVN
- Lead underwriters
- Morgan Stanley; Piper Sandler (2,772,000 shares)
- Syndicate
- Barclays (1,485,000); William Blair (1,188,000); Needham & Company (495,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Biohaven Pharmaceutical Holding Co Ltd. EXACT (CIK (EXACT))
- SEC filer: Biohaven Pharmaceutical Holding Co Ltd. EXACT (CIK (EXACT))
Filings 14
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-04-07 | S-1 | S-1 (registration) | Biohaven Pharmaceutical Holding Co Ltd. | 0001047469-17-002426 ↗ |
| 2017-04-24 | S-1/A | S-1/A (amendment) | Biohaven Pharmaceutical Holding Co Ltd. | 0001047469-17-002826 ↗ |
| 2017-05-01 | S-1/A | S-1/A (amendment) | Biohaven Pharmaceutical Holding Co Ltd. | 0001047469-17-003101 ↗ |
| 2017-05-03 | S-1MEF | S-1MEF (added securities) | Biohaven Pharmaceutical Holding Co Ltd. | 0001104659-17-029582 ↗ |
| 2017-05-03 | EFFECT | EFFECT (declared effective) | Biohaven Pharmaceutical Holding Co Ltd. | 9999999995-17-001174 ↗ |
| 2017-05-05 | 424B4 | 424B4 (final prospectus) | Biohaven Pharmaceutical Holding Co Ltd. | 0001047469-17-003184 ↗ |
| 2018-04-03 | S-1 | S-1 (registration) | Biohaven Pharmaceutical Holding Co Ltd. | 0001047469-18-002486 ↗ |
| 2018-04-05 | EFFECT | EFFECT (declared effective) | Biohaven Pharmaceutical Holding Co Ltd. | 9999999995-18-000767 ↗ |
| 2018-10-02 | S-1 | S-1 (registration) | Biohaven Pharmaceutical Holding Co Ltd. | 0001689813-18-000023 ↗ |
| 2018-10-17 | EFFECT | EFFECT (declared effective) | Biohaven Pharmaceutical Holding Co Ltd. | 9999999995-18-002648 ↗ |
| 2018-12-10 | S-1 | S-1 (registration) | Biohaven Pharmaceutical Holding Co Ltd. | 0001628280-18-014980 ↗ |
| 2018-12-12 | S-1MEF | S-1MEF (added securities) | Biohaven Pharmaceutical Holding Co Ltd. | 0001628280-18-015071 ↗ |
| 2018-12-12 | EFFECT | EFFECT (declared effective) | Biohaven Pharmaceutical Holding Co Ltd. | 9999999995-18-003115 ↗ |
| 2018-12-14 | 424B4 | 424B4 (final prospectus) | Biohaven Pharmaceutical Holding Co Ltd. | 0001628280-18-015109 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-05-01 | S-1/A | registration statement | $0.61 | 5,752,000 | $3,508,720 | 0 | primary document; price line, shares headline, proceeds computed | document ↗ | ||
| 2017-05-05 | 424B4 | final prospectus | $17.00 | 9,900,000 | $168,300,000 | NYSE BHVN | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| AGUIAR ERIC | Director | 15 | 2017–2020 | ||
| Bailey Gregory | Director | 26 | 2017–2022 | ||
| Berman Robert | Officer | Chief Medical Officer; Special Projects & Med Ovrsght | 23 | 2017–2020 | |
| Cha Albert | Director | 4 | 2017–2018 | ||
| CHILDS JOHN W | Director; Director,TenPercentOwner | 20 | 2017–2022 | ||
| Conway Charles | Officer | Chief Scientific Officer | 15 | 2017–2022 | |
| Coric Vlad | Director,Officer | Chief Executive Officer | 19 | 2017–2022 | |
| Doogan Declan | Director | 23 | 2017–2022 | ||
| Engelhart James | Officer | Chief Financial Officer; Strategic Advisor | 21 | 2017–2022 | |
| Gentile Kimberly | Officer | SVP, Clinical Operations; VP of Operations | 24 | 2017–2022 | |
| PORTAGE BIOTECH INC. | Other; TenPercentOwner | 7 | 2017–2018 | ||
| Tilton John | Officer | CCO-Rare & Neurologic Disorder; Chief Commercial Officer | 16 | 2017–2022 | |
| GREGORY JULIA P | Director | 12 | 2017–2022 | ||
| Repella Robert | Director | 3 | 2018–2019 | ||
| JONES WILLIAM A JR | Officer | CCO-Migraine & Common Disease | 10 | 2019–2022 | |
| Stock Elyse | Officer | Chief Medical Officer | 15 | 2019–2022 | |
| Heffernan Michael Thomas | Director | 8 | 2020–2022 | ||
| HUGIN ROBERT J | Director | 8 | 2020–2022 | ||
| Mehta Kishan | Director | 5 | 2021–2022 | ||
| Clark George C. | Officer | VP, Chief Accounting Officer | 8 | 2021–2022 | |
| Buten Matthew | Officer | Chief Financial Officer; Officer | 5 | 2021–2022 | |
| Antonijevic Irina | Director | 3 | 2022 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2016-11-10 | Biohaven Pharmaceutical Holding Co Ltd. | Pharmaceuticals | $80,000,000 | $40,000,127 | 34 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Biohaven Pharmaceutical Holding Co Ltd. | CT | Form D private offerings | CIK (EXACT) |
| IPO registrant | Biohaven Ltd. | CT | IPO registrations (S-1, F-1) | same street address and ZIP code, 215 CHURCH ST 06510 (FUZZY: a shared address, not proof of a shared organization) |
| Patent assignee | Biohaven Pharmaceutical Holding Company Ltd. | CT | Patents (USPTO) | name and state |
| SEC filer | Biohaven Pharmaceutical Holding Co Ltd. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CT first:
- CHIREX INC CT
- ACHILLION PHARMACEUTICALS INC CT
- Rib-X Pharmaceuticals, Inc. CT
- Oracle Healthcare Acquisition Corp. CT
- NANOVIRICIDES, INC. CT
- KOLLTAN PHARMACEUTICALS INC CT
- Trevi Therapeutics, Inc. CT
- Yarrow Bioscience, Inc. CT
- Loxo Oncology, Inc. CT
- ARVINAS, INC. CT
In other datasets, the same topic (Health) in CT:
- Nonprofit: AIDS BUDDY NETWORK (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health